keyword
MENU ▼
Read by QxMD icon Read
search

Ferric carboxymaltose

keyword
https://www.readbyqxmd.com/read/29149437/a-blinded-randomized-placebo-controlled-study-to-investigate-the-efficacy-and-safety-of-ferric-carboxymaltose-in-iron-deficient-patients-with-fibromyalgia
#1
Chad S Boomershine, Todd A Koch, David Morris
INTRODUCTION: This study sought to compare efficacy and safety of ferric carboxymaltose vs. placebo in iron-deficient patients with fibromyalgia. METHODS: This blinded, placebo-controlled, phase 2 study randomized adults with fibromyalgia and Revised Fibromyalgia Impact Questionnaire (FIQR) scores ≥ 60, ferritin levels < 0.05 µg/ml, and transferrin saturation < 20% (1:1) to receive ferric carboxymaltose [15 mg/kg (up to 750 mg)], or placebo (15 cc normal saline) intravenously on study days 0 and 5...
November 17, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29134606/intravenous-ferric-carboxymaltose-in-patients-with-type-2-diabetes-mellitus-and-iron-deficiency-clever-trial-study-design-and-protocol
#2
Christoph Schindler, Andreas L Birkenfeld, Markolf Hanefeld, Ulrike Schatz, Carsta Köhler, Martin Grüneberg, Diethelm Tschöpe, Matthias Blüher, Christoph Hasslacher, Stefan R Bornstein
INTRODUCTION: HbA1c is the gold standard for glycemic control in pre-diabetes and diabetes. However, its validity has been questioned, especially in the presence of imbalanced iron homeostasis. The CLEVER trial aims to evaluate the relationship between iron deficiency and HbA1c (a biomarker for the diagnosis and therapeutic monitoring of type 2 diabetes) in a randomized, placebo-controlled, multicenter clinical trial. METHODS: The CLEVER (intravenous ferric CarboxymaLtosE for improVement of mEtabolic parameters in type 2 diabetes patients with iRon deficiency) trial is a randomized, single-blind, proof-of-concept study with two treatment arms...
November 13, 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29118560/the-effectiveness-of-intravenous-iron-for-iron-deficiency-anemia-in-gastrointestinal-cancer-patients-a-retrospective-study
#3
Laurens Verhaeghe, Luk Bruyneel, Elisabeth Stragier, Marc Ferrante, Daan Dierickx, Hans Prenen
Background: Knowledge of the role of intravenous iron without the use of additional erythropoietic stimulating agents in anemic cancer patients is limited. This study evaluated the effect of ferric carboxymaltose (FCM) in a group of digestive oncology (DIO) patients and aimed to differentiate therapy response according to different types of iron deficiency (ID) anemia. Methods: In this retrospective study, we identified DIO patients who were receiving FCM and had eligible baseline and follow-up hemoglobin (Hb) levels that did not require red blood cell transfusion...
2017: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
https://www.readbyqxmd.com/read/29057687/safety-and-efficacy-of-intravenous-iron-administration-for-uterine-bleeding-or-postpartum-anaemia-a-narrative-review
#4
Angelos Daniilidis, Nikolaos Panteleris, Efthymia Vlachaki, Christian Breymann, Efstratios Assimakopoulos
The management of iron deficiency anaemia (IDA) consists of oral or intravenous administration of iron supplements. The aim of this narrative review is to summarise information regarding the treatment of IDA in women who have postpartum anaemia or uterine bleeding with intravenous (IV) or oral iron supplements. Fourteen randomised control studies comparing IV to oral iron treatment for IDA in 2913 women with uterine bleeding or postpartum haemorrhage are included. All reviewed studies suggest that IV iron administration is important in treating the IDA in such women and in improving their physical performance and quality of life...
October 23, 2017: Journal of Obstetrics and Gynaecology: the Journal of the Institute of Obstetrics and Gynaecology
https://www.readbyqxmd.com/read/29052292/intravenous-ferric-carboxymaltose-for-heart-failure-with-iron-deficiency
#5
EDITORIAL
Andrew J Stewart Coats
No abstract text is available yet for this article.
October 19, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/29033620/comparative-safety-of-intravenous-ferumoxytol-versus-ferric-carboxymaltose-for-the-treatment-of-iron-deficiency-anemia-rationale-and-study-design-of-a-randomized-double-blind-study-with-a-focus-on-acute-hypersensitivity-reactions
#6
N Franklin Adkinson, William E Strauss, Kristine Bernard, Robert F Kaper, Iain C Macdougall, Julie S Krop
BACKGROUND: Intravenous (IV) iron is often used to treat iron deficiency anemia in patients who are unable to tolerate or are inadequately managed with oral iron. However, IV iron treatment has been associated with acute hypersensitivity reactions. The comparative risk of adverse events (AEs) with IV iron preparations has been assessed by a few randomized controlled trials, which are most often limited by small patient numbers, which lack statistical power to identify differences in low-frequency AE such as hypersensitivity reactions...
2017: Journal of Blood Medicine
https://www.readbyqxmd.com/read/29032713/intravenous-iron-treatments-for-iron-deficiency-anemia-in-inflammatory-bowel-disease-a-budget-impact-analysis-of-iron-isomaltoside-1000-monofer-in-the-uk
#7
R F Pollock, G Muduma
Iron deficiency is the leading cause of anemia in patients with inflammatory bowel disease (IBD). Intravenous iron is the first-line treatment for clinically active IBD or previous oral iron intolerance. The aim of the present study was to develop a comparative model of iron deficiency and delivery for iron isomaltoside (IIM), ferric carboxymaltose (FCM), low molecular weight iron dextran (LMWID), and iron sucrose (IS) in the treatment of iron deficiency anemia associated with IBD. Areas covered: A model was developed to evaluate iron delivery characteristics, resource use and costs associated with IIM, FCM, LMWID and IS...
October 24, 2017: Expert Opinion on Drug Delivery
https://www.readbyqxmd.com/read/29016575/role-of-intravenous-ferric-carboxy-maltose-in-pregnant-women-with-iron-deficiency-anaemia
#8
Vineet Mishra, Khusaili Gandhi, Priyankur Roy, Shaheen Hokabaj, Kunur N Shah
BACKGROUND: Iron deficiency is a common nutritional deficiency amongst women of childbearing age. Peri-partum iron deficiency anaemia is associated with significant maternal, foetal and infant morbidity. Current options for treatment include oral iron, which can be ineffective and poorly tolerated, and red blood cell transfusions, which carry an inherent risk and should be avoided. Ferric carboxymaltose is a modern treatment option. The study was designed to assess the safety and efficacy of intravenous ferric carboxymaltose for correction of iron deficiency anaemia in pregnant women...
September 8, 2017: Journal of Nepal Health Research Council
https://www.readbyqxmd.com/read/28973244/ferric-carboxymaltose-to-treat-isovolemic-anemia-reply
#9
LETTER
Young-Woo Kim, Hannah Yang
No abstract text is available yet for this article.
October 3, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28973241/ferric-carboxymaltose-to-treat-isovolemic-anemia
#10
LETTER
Zhang Yu, Tiangui Li
No abstract text is available yet for this article.
October 3, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28940095/diagnosis-and-treatment-of-iron-deficiency-anaemia-in-pregnancy-and-postpartum
#11
C Breymann, C Honegger, I Hösli, D Surbek
Iron deficiency occurs frequently in pregnancy and can be diagnosed by serum ferritin-level measurement (threshold value < 30 μg/L). Screening for iron-deficiency anemia is recommended in every pregnant women, and should be done by serum ferritin-level screening in the first trimester and regular hemoglobin checks at least once per trimester. In the case of iron deficiency with or without anaemia in pregnancy, oral iron therapy should be given as first-line treatment. In the case of severe iron-deficiency anemia, intolerance of oral iron, lack of response to oral iron, or in the case of a clinical need for rapid and efficient treatment of anaemia (e...
September 22, 2017: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/28921558/safety-and-efficacy-of-intravenous-iron-polymaltose-iron-sucrose-and-ferric-carboxymaltose-in-pregnancy-a-systematic-review
#12
REVIEW
Alaa Qassim, Ben W Mol, Rosalie M Grivell, Luke E Grzeskowiak
BACKGROUND: Intravenous (IV) iron in pregnancy is useful where oral iron is not tolerated or a rapid replenishment of iron is required. AIMS: To review the literature on the efficacy and safety of different IV iron preparations in the management of antenatal iron-deficiency anaemia (IDA). MATERIALS AND METHODS: We searched MEDLINE, Embase and Scopus from inception to June 2016. Eligible studies were randomised controlled trials (RCTs) and observational studies, involving administration of IV iron (ferric carboxymaltose (FCM), iron polymaltose (IPM) or iron sucrose (IS)), regardless of comparator, to manage antenatal IDA...
September 18, 2017: Australian & New Zealand Journal of Obstetrics & Gynaecology
https://www.readbyqxmd.com/read/28844092/retrospective-review-of-effectiveness-and-safety-of-intravenous-ferric-carboxymaltose-given-to-children-with-iron-deficiency-anaemia-in-one-uk-tertiary-centre
#13
Michelle Li Nien Tan, Paul-Michael Windscheif, Graham Thornton, Ed Gaynor, Astor Rodrigues, Lucy Howarth
In the paediatric population, ferric carboxymaltose (FCM) is only licenced for use in children older than 14 years, and the data in younger children remains scarce. We retrospectively reviewed data of all paediatric patients less than 14 years old who had received FCM infusion from August 2011 to June 2015 at the John Radcliffe Hospital (Oxford University Hospitals), UK. The patient demographics, significant medical history, FCM dose, and blood investigations (pre-FCM and post-FCM) were reviewed. Of the 51 children, 41 had inflammatory bowel disease...
October 2017: European Journal of Pediatrics
https://www.readbyqxmd.com/read/28814833/markers-of-oxidative-nitrosative-stress-and-inflammation-in-lung-tissue-of-rats-exposed-to-different-intravenous-iron-compounds
#14
Jorge E Toblli, Gabriel Cao, Jorge F Giani, Fernando P Dominici, Margarita Angerosa
Iron deficiency anemia is a frequent complication in clinical conditions such as chronic kidney disease, chronic heart failure, inflammatory bowel disease, cancer, and excessive blood loss. Given the ability of iron to catalyze redox reactions, iron therapy can be associated with oxidative stress. The lung is uniquely susceptible to oxidative stress, and little is known about the effects of intravenous iron treatment in this organ. This study characterized changes in markers of oxidative/nitrosative stress and inflammation in the lung of non-iron deficient, non-anemic rats treated with five weekly doses (40 mg iron per kg body weight) of low molecular weight iron dextran (LMWID), iron sucrose (IS), ferric carboxymaltose (FCM), ferumoxytol (FMX), iron isomaltoside 1000 (IIM), or saline (control)...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28772041/budget-impact-of-intravenous-iron-therapy-with-ferric-carboxymaltose-in-patients-with-chronic-heart-failure-and-iron-deficiency-in-germany
#15
Ulrike Theidel, Saku Väätäinen, Janne Martikainen, Erkki Soini, Thomas Hardt, Wolfram Doehner
AIMS: Treatment of iron deficiency (ID) in patients with heart failure (HF) with intravenous iron substitution [ferric carboxymaltose (FCM)] has previously shown significant improvements in exercise capacity, New York Heart Association (NYHA) functional class, quality of life, and reduction of hospitalization. The aim of this study was to estimate the budget impact of FCM treatment for patients with HF and ID. METHODS AND RESULTS: Individual patient data from four double-blind randomized controlled trials were pooled for this analysis...
August 2017: ESC Heart Failure
https://www.readbyqxmd.com/read/28761876/sustainability-of-endovenous-iron-deficiency-anaemia-treatment-hospital-based-health-technology-assessment-in-ibd-patients
#16
A Poscia, J Stojanovic, F Kheiraoui, E M Proli, F Scaldaferri, M Volpe, M L Di Pietro, A Gasbarrini, L Fabrizio, S Boccia, C Favaretti
Iron deficiency anaemia (IDA) is the main extraintestinal manifestation affecting patients with inflammatory bowel disease (IBD). The Health Technology Assessment approach was applied to evaluate the sustainability of intravenous (IV) iron formulations in the Italian hospital setting, with particular focus on ferric carboxymaltose. Data on the epidemiology of IBD and associated IDA, in addition to the efficacy and safety of IV iron formulations currently used in Italy, were retrieved from scientific literature...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28758033/efficacy-and-tolerability-of-intravenous-ferric-carboxymaltose-in-patients-with-iron-deficiency-at-a-hospital-outpatient-clinic-a-retrospective-cohort-study-of-real-world-clinical-practice
#17
António Robalo Nunes, Ana Palricas Costa, Sara Lemos Rocha, Ana Garcia de Oliveira
Ferric carboxymaltose (FCM) is an intravenous iron formulation to correct iron deficiency. Although its use has been extensively studied in clinical trials, real-world evidence regarding FCM treatment is scarce. Our aim was to evaluate the efficacy and tolerability of FCM treatment in patients with iron deficiency, with or without anemia, at a hospital outpatient clinic. Data was collected retrospectively from medical records. During this 2-year study, 459 patients were included. Mean age was 58.6 ± 17.5 years and most patients received cumulative FCM doses of 501-1000 mg (63...
2017: Anemia
https://www.readbyqxmd.com/read/28706363/comparative-study-of-efficacy-and-safety-of-ferric-carboxymaltose-versus-iron-sucrose-in-post-partum-anaemia
#18
Nalini Sharma, J Lalnunnem Thiek, Tanie Natung, Santa Singh Ahanthem
BACKGROUND: The incidence of post-partum anaemia (PPA) is 14-24%. Treatment of PPA with injectable iron replenishes the iron store. Ferric carboxymaltose complex (FCM) is a non-dextran containing intravenous iron agent, having a very low immunogenic potential, designed to be administered in large doses in a short period of time. OBJECTIVE: To compare the efficacy and safety of intravenous FCM and iron sucrose (IS) in post-partum iron-deficiency anaemia. MATERIAL AND METHOD: In this prospective, comparative study, 120 post-partum women with iron-deficiency anaemia (Hb < 10 g%) were divided into two groups...
August 2017: Journal of Obstetrics and Gynaecology of India
https://www.readbyqxmd.com/read/28701470/effect-of-ferric-carboxymaltose-on-exercise-capacity-in-patients-with-chronic-heart-failure-and-iron-deficiency
#19
MULTICENTER STUDY
Dirk J van Veldhuisen, Piotr Ponikowski, Peter van der Meer, Marco Metra, Michael Böhm, Artem Doletsky, Adriaan A Voors, Iain C Macdougall, Stefan D Anker, Bernard Roubert, Lorraine Zakin, Alain Cohen-Solal
BACKGROUND: Iron deficiency is common in patients with heart failure (HF) and is associated with reduced exercise capacity and poor outcomes. Whether correction of iron deficiency with (intravenous) ferric carboxymaltose (FCM) affects peak oxygen consumption [peak VO2], an objective measure of exercise intolerance in HF, has not been examined. METHODS: We studied patients with systolic HF (left ventricular ejection fraction ≤45%) and mild to moderate symptoms despite optimal HF medication...
October 10, 2017: Circulation
https://www.readbyqxmd.com/read/28701129/iron-deficiency-and-new-insights-into-therapy
#20
REVIEW
Michael Sy Low, George Grigoriadis
Iron deficiency and iron deficiency anaemia remain prevalent in Australia. The groups at highest risk are pre-menopausal women, socially disadvantaged people and those of Indigenous background. Diagnosing iron deficiency using a full blood examination and iron studies can be difficult and can be further complicated by concomitant inflammation. Results of iron studies should always be interpreted as an overall picture rather than focusing on individual parameters. In difficult clinical scenarios, soluble transferrin receptor assays can be useful...
July 17, 2017: Medical Journal of Australia
keyword
keyword
11331
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"